Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Frontiers in Neuroscience|July 3, 2020
LRRK2 Phosphorylation, More Than an EpiphenomenonAntoine Marchand, Matthieu Drouyer, Alessia Sarchione, et al.
The European Journal of Neuroscience|April 20, 2004
Dopamine receptor-mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and timeJean-Marc Taymans, Hossein Kami Kia, Robby Claes, et al.
International Journal of Molecular Sciences|January 18, 2014
In vitro phosphorylation does not influence the aggregation kinetics of WT α-synuclein in contrast to its phosphorylation mutantsSarah Schreurs, Melanie Gerard, Rita Derua, et al.
Expert Opinion on Therapeutic Patents|July 18, 2024
Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to dateMargaux Morez, Antonio Jesús Lara Ordóñez, Patricia Melnyk, et al.
BMC Neuroscience|August 10, 2010
Automated quantitative gait analysis in animal models of movement disordersCaroline Vandeputte, Jean-Marc Taymans, Cindy Casteels, et al.
Biochimica Et Biophysica Acta|January 19, 2012
Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2Renée Vancraenenbroeck, Evy Lobbestael, Stephen D Weeks, et al.
Plos One|January 22, 2010
The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylationAzad Kumar, Elisa Greggio, Alexandra Beilina, et al.
Plos One|August 23, 2011
LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP bindingJean-Marc Taymans, Renée Vancraenenbroeck, Petri Ollikainen, et al.
Frontiers in Molecular Neuroscience|June 12, 2014
In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2Renée Vancraenenbroeck, Joren De Raeymaecker, Evy Lobbestael, et al.
NPJ Parkinson'S Disease|July 1, 2023
Perspective on the current state of the LRRK2 fieldJean-Marc Taymans, Matt Fell, Tim Greenamyre, et al.
Pageof 7